AccessMyLibraryBrowseMM2 PresswireFEB-05 U.S. biodefense and ucl biomedica sign option agreement to license patent rights applications related to development of artificial liver and therapeutic re-population in patients with liver disease.
U.S. biodefense and ucl biomedica sign option agreement to license patent rights applications related to development of artificial liver and therapeutic re-population in patients with liver disease.
Publication: M2 Presswire
Publication Date: 24-FEB-05
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
M2 PRESSWIRE-24 February 2005-FNWU: U.S. biodefense and ucl biomedica sign option agreement to license patent rights applications related to development of artificial liver and therapeutic re-population in patients with liver disease(C)1994-2005 M2 COMMUNICATIONS LTD
RDATE:24022005
City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). U.S. BioDefense (OTCBB: UBDE) announced that it has signed a 90 day option to license European Patent Application No.
02743434.9, and US patent application 10/483,190 entitled "Liver cell progenitor and use...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
